Scarica l'app Stockscreener
68.42
1.27%
0.83
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Precedente Chiudi:
$67.59
Aprire:
$67.72
Volume 24 ore:
54,313
Relative Volume:
0.04
Capitalizzazione di mercato:
$7.26B
Reddito:
$628.56M
Utile/perdita netta:
$141.82M
Rapporto P/E:
54.30
EPS:
1.26
Flusso di cassa netto:
$142.60M
1 W Prestazione:
-3.40%
1M Prestazione:
-7.49%
6M Prestazione:
+14.10%
1 anno Prestazione:
+96.29%
Intervallo 1D:
$67.69
$68.67
Intervallo di 1 settimana:
$67.44
$71.57
Portata 52W:
$32.33
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Nome
Corcept Therapeutics Inc
Settore
Industria
Telefono
650.688.8803
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Confronta CORT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
68.44 | 7.25B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.84 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.55 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.43 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.46 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.49 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-06 | Aggiornamento | Truist | Hold → Buy |
| 2023-04-11 | Iniziato | SVB Securities | Market Perform |
| 2023-04-04 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-01 | Downgrade | Truist | Buy → Hold |
| 2022-07-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-06-27 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-02 | Iniziato | Canaccord Genuity | Buy |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2020-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-09-24 | Iniziato | Jefferies | Buy |
| 2019-09-06 | Iniziato | H.C. Wainwright | Buy |
| 2019-02-04 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Reiterato | Stifel | Hold |
| 2018-05-31 | Downgrade | Stifel | Buy → Hold |
| 2018-03-09 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Iniziato | Stifel | Buy |
| 2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-04-21 | Iniziato | FBR Capital | Outperform |
| 2014-01-13 | Downgrade | Stifel | Buy → Hold |
| 2013-08-09 | Downgrade | Janney | Buy → Neutral |
| 2013-08-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-01-06 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Aggiornamento | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Mostra tutto
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
What analysts say about Corcept Therapeutics Incorporated stockExceptional financial outcomes - Autocar Professional
Is Corcept Therapeutics Incorporated stock overhyped or has real potentialFree Market Dynamics Reports - jammulinksnews.com
Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant - Yahoo Finance
Should I buy Corcept Therapeutics Incorporated stock before earningsTriple-digit returns - jammulinksnews.com
What drives Corcept Therapeutics Incorporated stock priceFree Predictions - Autocar Professional
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects - Yahoo Finance
Is Corcept Therapeutics Incorporated a good long term investmentFree Wealth Management Insights - jammulinksnews.com
Corcept Therapeutics Incorporated Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional
Corcept Therapeutics (NASDAQ:CORT): A High-Conviction Buy in the Biopharma Sector Amid EPS Growth and Strategic Momentum - AInvest
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching - Yahoo Finance
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga
Corcept Therapeutics Incorporated (NASDAQ:CORT) is largely controlled by institutional shareholders who own 70% of the company - simplywall.st
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know - TradingView
FDA approval sought of relacorilant for platinum-resistant ovarian cancer - Rare Cancer News
M&T Bank Corp Sells 3,530 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock - Defense World
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer - Yahoo Finance
Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionShort Term Profit Focus - Newser
How rare disease-focused Corcept Therapeutics expanded into cancerSan Francisco Business Times - The Business Journals
Corcept seeks FDA approval for ovarian cancer treatment (CORT) - Seeking Alpha
Corcept Therapeutics' Relacorilant NDA Submission: A Breakthrough in Ovarian Cancer and a Strategic Pivot to Oncology - AInvest
Corcept Therapeutics Submits New Drug Application to FDA - TipRanks
Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer - MarketScreener
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Corcept Therapeutics’ Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients - MSN
Piper Sandler reiterates Overweight rating on Corcept Therapeutics stock By Investing.com - Investing.com Canada
Corcept Therapeutics: A New Standard of Care in Ovarian Cancer Emerges - AInvest
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial - MSN
13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey
A New Dawn in Diabetes Treatment: Corcept Therapeutics' Korlym and the Untapped $2.8 Billion Opportunity - AInvest
Corcept therapeutics officer Guyer sells $7350 in shares By Investing.com - Investing.com Canada
Corcept therapeutics officer Guyer sells $7350 in shares - Investing.com
Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players | DelveInsight - The Globe and Mail
10 Best NASDAQ Growth Stocks to Buy for the Next 3 Years - Insider Monkey
Corcept Therapeutics (NasdaqCM:CORT) Dropped From Russell 2000 and Growth Index - Yahoo Finance
Corcept Therapeutics Incorporated(NasdaqCM: CORT) added to Russell Midcap Index - MarketScreener
Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint - Yahoo Finance
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85 - Business Wire
Insider Decision: Gary Charles Robb Offloads $225K Worth Of Corcept Therapeutics Stock - Nasdaq
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayCorcept Therapeutics (NASDAQ:CORT) - Benzinga
Corcept reports annual meeting outcomes By Investing.com - Investing.com Canada
Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances - Investing.com Canada
Corcept Therapeutics director Daniel Swisher sells $155k in stock By Investing.com - Investing.com UK
Corcept Therapeutics director Daniel Swisher sells $155k in stock - Investing.com Australia
Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Corcept Therapeutics Inc Azioni (CORT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Maduck Sean | See Remarks |
Jul 18 '25 |
Option Exercise |
5.05 |
473 |
2,389 |
18,178 |
| Maduck Sean | See Remarks |
Jul 17 '25 |
Sale |
73.48 |
4,315 |
317,054 |
17,705 |
| Maduck Sean | See Remarks |
Jul 18 '25 |
Sale |
73.44 |
473 |
34,737 |
17,705 |
| BELANOFF JOSEPH K | Chief Executive Officer |
Jul 17 '25 |
Sale |
73.69 |
615 |
45,318 |
2,901,370 |
| Lyon Joseph Douglas | See Remarks |
Jul 17 '25 |
Option Exercise |
13.56 |
3,877 |
52,572 |
13,943 |
| Lyon Joseph Douglas | See Remarks |
Jul 18 '25 |
Option Exercise |
13.56 |
200 |
2,712 |
10,266 |
| Lyon Joseph Douglas | See Remarks |
Jul 17 '25 |
Sale |
73.48 |
3,877 |
284,864 |
10,066 |
| Lyon Joseph Douglas | See Remarks |
Jul 18 '25 |
Sale |
73.40 |
200 |
14,680 |
10,066 |
| Guyer William | Chief Development Officer |
Jul 17 '25 |
Option Exercise |
21.65 |
4,379 |
94,805 |
9,866 |
| Guyer William | Chief Development Officer |
Jul 18 '25 |
Option Exercise |
21.65 |
500 |
10,825 |
5,987 |
1.74%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):